Findings define mechanisms by which tumors restrict targetable truncal truncal neoantigen display and suggest immunopeptidome shift strategies to circumvent immune escape.
Abstract
SUMMARY TP53 mutations occur early in malignant transformation as truncal events and are therefore generally present in all tumor cells, creating an immunological vulnerability. Here, we examined the immunogenicity and antigenicity of p53 truncal neoantigens. Comprehensive immunopeptidomics revealed that hotspot mutations in human tumors preferentially localize to p53 regions resistant to antigen processing, thereby avoiding display altogether. Moreover, for neoantigens presentable by HLA-A*02:01 or HLA-B*07:02 and structurally divergent from corresponding wild-type p53 peptide-HLA complexes, clinical tumors commonly lacked the relevant presenting HLA allele. Tumor cells further resisted CTL killing through increased ERAP1 activity, preventing display of high-affinity HLA-A*02:01 complexes containing an immunogenic p53I195F-derived 11-mer, or by expressing low-affinity HLA-A*02:01 complexes containing a p53R175H-derived 9-mer with poor antigenicity despite high-quality human TCRs. These findings define mechanisms by which tumors restrict targetable truncal neoantigen display and suggest immunopeptidome shift strategies to circumvent immune escape.
Adoptive cell therapy (ACT) with tumor-specific T cells can mediate durable cancer regression. The main target of tumor-specific T cells are neoantigens resulting from mutations in self-antigens over the course of malignant transformation. To understand T-cell recognition of cancer neoantigens at the atomic level, we s...
Dual immunological identity of mutant p53 (mut-p53) functions as the context-dependent determinant of tumor immunogenicity and cancer immunotherapy outcome, underscoring its promise as both a biomarker and a therapeutic target in crafting next-generation precision cancer immunotherapy strategies.
S. Chakraborty, S. Mukherjee, Subhajit Ghosh et al.· Apoptosis· 0 citations
This review outlines the molecular mechanisms driving neoantigen generation in CRC, including frameshift mutations, single-nucleotide variants, alternative RNA splicing, and circular RNA-derived epitopes, and evaluates neoantigen-directed therapeutic platforms, encompassing personalized neoantigen vaccines and adoptive...
Na Wang, Yi-Meng Xia, Ping Wang et al.· Medical Oncology· 0 citations
This work provides a framework for identifying actionable treatment-induced peptide antigens and supports rational combination strategies pairing KRAS/RAS inhibitors with T cell-based immunotherapies, including BiTE, CAR-pMHC, TCR-T, and cancer vaccine approaches.
Wei-Xia Kang, Allison Glynn, Harshabad Singh et al.· Cancer Research· 0 citations
This review integrates current understanding of the biological origins, immunological barriers, target classes of splicing neoantigens, and the technologies that enable their advancement in cancer immunotherapy to produce two major classes of immunotherapeutic targets.
Mu-Tian Tang, H. L. Grimes, Nathan Salomonis· Frontiers in Immunology· 0 citations